Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer
β Scribed by Edoardo Beretta; Alberto Malesci; Alessandro Zerbi; Alberto Mariani; Michele Carlucci; Claudio Bonato; Anna Maria Ferrari; Valerio Di Carlo
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 356 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Background and Objectives: Pancreatic cancer is generally a disease with a poor prognosis, and relationship between change of serum CA 19-9 level and progression of this disease was investigated with regard to clinical pace of disease and tumor growth. Methods: CA 19-9 doubling time was examined in
Neuroendocrine (NE) differentiation of prostatic adenocarcinomas has received increasing attention in recent years as a result of possible implications on prognosis and therapy. The incidence of NE cells in tumors has been reported from 10% up to 100%. Several studies have shown chromogranin A (CgA)
Background and Objectives: CA19-9 is a cancer-associated carbohydrate antigen that plays a role in the process of tumor progression as an adhesion molecule. Methods: We evaluated the prognostic value of CA19-9 tumor expression and CA19-9 preoperative and postoperative serum levels in colorectal canc
Our aim was to evaluate the clinical usefulness of serum concentrations of squamous-cell carcinoma antigen (SCC-Ag) and tissue polypeptide antigen (TPA) in the follow-up of patients with vulvar cancer. We measured SCC-Ag and TPA in 480 serum samples of 82 patients with squamous-cell vulvar cancer. R